Research programme: bispecific antibodies - Genmab/Janssen Biotech

Drug Profile

Research programme: bispecific antibodies - Genmab/Janssen Biotech

Alternative Names: Ab 957; BCMAxCD3 bispecific antibody; EM1-mAb DuoBody

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab; Janssen Biotech
  • Developer Genmab
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Epidermal growth factor receptor modulators; Immunomodulators; Proto oncogene protein c met modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 03 Dec 2016 Janssen plans a phase I trial for Multiple myeloma
  • 14 Jul 2014 Preclinical trials in Autoimmune disorders in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top